Please ensure Javascript is enabled for purposes of website accessibility

Stock Market News: Tilray Comes Down; Thermo Fisher Makes a Big Buy

By Dan Caplinger - Mar 3, 2020 at 11:48AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stock market was turbulent Tuesday morning.

The stock market saw considerable volatility on Tuesday morning, initially giving up ground on renewed fears about the global spread of the COVID-19 outbreak. Stocks briefly bounced higher after the Federal Reserve announced that it would cut interest rates by half a percentage point in an unusual move between meetings of the Federal Open Market Committee, showing that central banks remain on guard to support the economy in the face of potential disruptions related to the coronavirus.

Yet market participants quickly lost confidence in the move, and by 11:30 a.m. EST, the Dow Jones Industrial Average (^DJI 2.68%) was down 477 points to 26,227. The S&P 500 (^GSPC 3.06%) had fallen 58 points to 3,032, and the Nasdaq Composite (^IXIC 3.34%) had dropped 133 points to 8,820.

Earnings season has largely ended, but news continued to trickle in from the cannabis sector, as Tilray (TLRY) gave its latest reading on conditions among marijuana stocks. Meanwhile, Thermo Fisher Scientific (TMO 0.78%) took advantage of big declines in stock markets to announce a strategic acquisition that could have major implications for its growth.

Tilray sees red

Shares of Tilray fell 12% to hit an all-time low following the release of its fourth-quarter financial report. The company failed to satisfy investors, calling into question the entire pathway to profitability for the cannabis company.

Two-story building with Tilray logo on the side, and parking lot and trees nearby.

Image source: Tilray.

Tilray's financial results were mixed. The company reported the same kind of revenue growth that cannabis investors have come to expect, with fourth-quarter revenue tripling from year-earlier levels. But it posted a net loss seven times larger than its loss from last year's fourth quarter, due in part to impairment charges tied to its revenue-sharing arrangement with footwear specialist Authentic Brands Group.

Moreover, Tilray has had to resort to expensive financing in order to support its ongoing losses. The cannabis grower announced a senior credit facility with a two-year term bearing an interest rate 8 full percentage points higher than the prime rate. Tilray did still have $97 million in cash as of the end of 2019, but it could take more spending to pursue growth opportunities.

Executives remain optimistic, but shareholders don't seem so sure. With the stock having lost 95% of its value from its peak shortly after its 2018 IPO, Tilray no longer has investors feeling confident about what's coming down the road.

Thermo shows the rumors were true

Elsewhere, shares of Thermo Fisher Scientific jumped 6%. The company announced a long-rumored major purchase of an industry peer, opening a new pathway to potential growth.

Thermo Fisher said Tuesday that it would buy medical technology company specialist Qiagen (QGEN 4.01%) in an $11.5 billion acquisition. Under the terms of the deal, Thermo Fisher will assume $1.4 billion in net debt from Qiagen, and Qiagen shareholders will receive 39 euros per share in cash, worth roughly $43.60 per share at current exchange rates. Qiagen shares jumped 15% on the news.

Thermo Fisher pointed to the complementary nature of the two businesses, with the hope that Qiagen's life science and molecular diagnostic solutions will help add to Thermo Fisher's broader set of diagnostic offerings. From a geographical standpoint as well, the two companies will be able to benefit from cross-selling each other's existing portfolios of products. Cost savings from synergies should amount to roughly $200 million annually within a few years of the deal's closing.

Consolidation in the healthcare industry has ramped up lately, and Thermo Fisher has found a nice fit in Qiagen. Investors will have to wait and see whether the two companies can get the necessary approvals, but with Thermo Fisher hoping to close the deal in the first half of 2021, shareholders of both stocks seem excited by the possibilities.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

QIAGEN N.V. Stock Quote
QIAGEN N.V.
QGEN
$46.63 (4.01%) $1.80
Thermo Fisher Scientific Inc. Stock Quote
Thermo Fisher Scientific Inc.
TMO
$544.81 (0.78%) $4.21
Tilray Stock Quote
Tilray
TLRY
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
^DJI
$31,500.68 (2.68%) $823.32
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
^GSPC
$3,911.74 (3.06%) $116.01
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
^IXIC
$11,607.62 (3.34%) $375.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.